NASDAQ:ADMP

Adamis Pharmaceuticals Stock Forecast, Price & News

$1.07

+0.04 (+3.88 %)

(As of 07/29/2021 02:05 PM ET)

Add

Compare

Today's Range

$1.03

▼

$1.10

50-Day Range

$0.67

▼

$1.23

52-Week Range

$0.38

▼

$2.34

Volume82,150 shs

Average Volume12.69 million shs

Market Capitalization$159.31 million

P/E RatioN/A

Dividend YieldN/A

Beta1.29

30 days | 90 days | 365 days | Advanced Chart

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

Adamis Pharmaceuticals Corporation Common Stock (ADMP)
July 25, 2021 | nasdaq.com

Brokerages Anticipate Adamis Pharmaceuticals Co. (NASDAQ:ADMP) Will Post Quarterly Sales of $3.09 Million
July 25, 2021 | americanbankingnews.com

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) Expected to Post Earnings of -$0.06 Per Share
July 23, 2021 | americanbankingnews.com

Adamis Announces Results of 2021 Annual Meeting of Stockholders
July 19, 2021 | finance.yahoo.com

Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th
July 13, 2021 | finance.yahoo.com

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) Expected to Post Quarterly Sales of $3.09 Million
July 4, 2021 | americanbankingnews.com

Adamis Sends Letter to Stockholders to Address Jerald A. Hammann's Costly, Distracting and Misguided Campaign
July 2, 2021 | benzinga.com

Adamis Sends Letter to Stockholders to Address Jerald A. Hammann’s Costly, Distracting and Misguided Campaign
July 1, 2021 | finance.yahoo.com

Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
June 28, 2021 | finance.yahoo.com

Are Options Traders Betting on a Big Move in Adamis Pharmaceuticals (ADMP) Stock?
June 18, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMP
Previous Symbol
CUSIPN/A
CIK887247
Webwww.adamispharmaceuticals.com
Phone858-997-2400
Employees116
Year FoundedN/A

Sales & Book Value

Annual Sales$16.53 million
Price / Sales9.64
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.03 per share
Price / Book35.67

Profitability

EPS (Most Recent Fiscal Year)($0.51)
Net Income$-49,390,000.00
Net Margins-298.85%
Return on Equity-176.31%
Return on Assets-96.27%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares148,886,000
Market Cap$159.31 million
Next Earnings Date8/16/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.47 out of 5 stars

Medical Sector

986th out of 2,214 stocks

Pharmaceutical Preparations Industry

474th out of 869 stocks

3.0 Analyst's Opinion

Consensus Rating
Adamis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.50, Adamis Pharmaceuticals has a forecasted upside of 39.5% from its current price of $1.08.
Amount of Analyst Coverage
Adamis Pharmaceuticals has received no research coverage in the past 90 days.

3.7 Community Rank

Outperform Votes
Adamis Pharmaceuticals has received 333 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Adamis Pharmaceuticals has received 112 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Adamis Pharmaceuticals has received 74.83% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote “Outperform” if you believe ADMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Adamis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Adamis Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adamis Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Adamis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 8.43% of the stock of Adamis Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Adamis Pharmaceuticals are expected to grow in the coming year, from ($0.24) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adamis Pharmaceuticals is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adamis Pharmaceuticals is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adamis Pharmaceuticals has a P/B Ratio of 35.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

Is Adamis Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adamis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View analyst ratings for Adamis Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Adamis Pharmaceuticals?

Wall Street analysts have given Adamis Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adamis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adamis Pharmaceuticals?

Adamis Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 11,380,000 shares, an increase of 23.3% from the June 30th total of 9,230,000 shares. Based on an average daily volume of 8,540,000 shares, the short-interest ratio is presently 1.3 days.
View Adamis Pharmaceuticals' Short Interest.

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 16th 2021.
View our earnings forecast for Adamis Pharmaceuticals.

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) announced its quarterly earnings data on Wednesday, April, 14th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.18. The specialty pharmaceutical company had revenue of $3.64 million for the quarter. Adamis Pharmaceuticals had a negative net margin of 298.85% and a negative trailing twelve-month return on equity of 176.31%.
View Adamis Pharmaceuticals' earnings history.

How has Adamis Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Adamis Pharmaceuticals' stock was trading at $0.4029 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMP shares have increased by 165.6% and is now trading at $1.07.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ADMP?

3 Wall Street analysts have issued 12 month price targets for Adamis Pharmaceuticals' shares. Their forecasts range from $1.50 to $1.50. On average, they anticipate Adamis Pharmaceuticals' share price to reach $1.50 in the next year. This suggests a possible upside of 40.2% from the stock's current price.
View analysts' price targets for Adamis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the following people:

Dr. Dennis J. Carlo, Pres, CEO & Director (Age 78, Pay $982.81k)
Mr. Robert O. Hopkins, Sr. VP of Fin., CFO & Sec. (Age 61, Pay $579.96k)
Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 51)
Dr. Ronald B. Moss, Chief Medical Officer (Age 60, Pay $613.65k)
Ms. Karen K. Daniels, VP of Operations (Age 68)
Mr. David C. Benedicto, Principal Accounting Officer (Age 60)
Mr. Mark Flather, Sr. Director of Investor Relations & Corp. Communications
Ms. Jennifer C. Suski, Sr. Director of Marketing
Mr. Eddie Wabern Glover, Chief Exec. Officer of US Compounding Inc (Age 71)
Mr. Robert B. Rothermel, Consultant (Age 77)

Who are some of Adamis Pharmaceuticals' key competitors?

Some companies that are related to Adamis Pharmaceuticals include BioXcel Therapeutics (BTAI), Karyopharm Therapeutics (KPTI), PyroGenesis Canada (PYR), Eagle Pharmaceuticals (EGRX), Catalyst Pharmaceuticals (CPRX), Cara Therapeutics (CARA), Praxis Precision Medicines (PRAX), Chimerix (CMRX), Zomedica (ZOM), Evolus (EOLS), Gossamer Bio (GOSS), Intercept Pharmaceuticals (ICPT), Chinook Therapeutics (KDNY), Verastem (VSTM) and Veru (VERU).
View all of ADMP's competitors.

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $1.07.

How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals has a market capitalization of $159.31 million and generates $16.53 million in revenue each year. The specialty pharmaceutical company earns $-49,390,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Adamis Pharmaceuticals have?

Adamis Pharmaceuticals employs 116 workers across the globe.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com.

Where are Adamis Pharmaceuticals' headquarters?

Adamis Pharmaceuticals is headquartered at 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here